Endocannabinoid inhibition: a new cardioprotective strategy against doxorubicin cardiotoxicity

J Am Coll Cardiol. 2007 Aug 7;50(6):537-9. doi: 10.1016/j.jacc.2007.04.052. Epub 2007 Jul 23.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / adverse effects*
  • Cannabinoid Receptor Modulators / antagonists & inhibitors
  • Doxorubicin / adverse effects*
  • Endocannabinoids
  • Heart Failure / chemically induced*
  • Heart Failure / prevention & control
  • Morpholines / pharmacology*
  • Morpholines / therapeutic use
  • Piperidines / pharmacology*
  • Piperidines / therapeutic use
  • Pyrazoles / pharmacology*
  • Pyrazoles / therapeutic use
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors*
  • Rimonabant

Substances

  • Antibiotics, Antineoplastic
  • Cannabinoid Receptor Modulators
  • Endocannabinoids
  • Morpholines
  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Doxorubicin
  • Rimonabant
  • AM 281